Salmonella

Composición de vacuna que comprende un sistema para suministrar una bacteria entera inactivada a través de nanopartículas de polisacáridos catiónicos sin ningún adyuvante

Resumen de: MX2025009500A

The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.

アセトキシ水素化ホウ素類を用いた糖抗原のコンジュゲーション

Resumen de: CN120418260A

The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.

DETECTION OF PATHOGENIC E. COLI STRAINS

Resumen de: WO2025233323A1

The invention relates to compositions of binding peptides, and individual binding peptides, capable of specific binding to either of two variants of OmpA occurring in pathogenic E. coli, and to methods employing these binding peptides for detection or isolation of pathogenic E. coli.

ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF

Resumen de: US2025345369A1

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

항-박테리아 단백질 복합체

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

一种马链球菌和马流产沙门菌二联融合抗原及应用

Resumen de: CN120924562A

本发明公开了一种马链球菌和马流产沙门菌二联融合抗原，其核苷酸序列如SEQ ID NO.1所示。本发明将马流产沙门菌的FljB与马链球菌的SeM、EAG、GAPDH部分抗原串联重组在一起，不仅可以同时预防马链球菌和马流产沙门菌2种不同的马传染病，还增强了小鼠的体液免疫应答水平，利用该融合抗原免疫可获得抵抗马链球菌和马流产沙门菌的攻毒保护效果，高于单独抗原蛋白的免疫和灭活全菌的免疫，这解决了以往灭活疫苗免疫效率低和免疫繁琐的问题，有利于降低免疫的成本。

抗细菌蛋白质复合物

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

PHAGE LYASE AND USE THEREOF

Resumen de: WO2025227308A1

A phage lyase with an amino acid sequence set forth in SEQ IN NO.2. The lyase can inhibit the growth of Staphylococcus, Escherichia, Klebsiella, and Salmonella bacteria, and can be used as an antibacterial substance in milk pollution control, belonging to the field of bioengineering. The phage lyase can be used for preparing an enzyme formulation alone or in a compounded manner to specifically inactivate bacteria such as Staphylococcus aureus, thereby providing an enzyme formulation source which is safe and free of toxic and side effects for controlling Staphylococcus aureus pollution in milk at present.

弱毒化サルモネラ・チフィムリウム（Ｓａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍ）を使用する良性神経系腫瘍の処置

Resumen de: US2022125906A1

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

PD-L1 Salmonella mutant expressing anti-PD-L1 peptide and outer membrane vesicle thereof and pharmaceutical comprising the same

Resumen de: KR20230091594A

The present invention relates to a Salmonella mutant strain expressing anti-PD-L1 peptide, outer membrane vesicles thereof, and a pharmaceutical composition containing the same. The Salmonella mutant strain expresses the anti-PD-L1 peptide in an extracellular loop of an outer membrane protein A, and thus, the anti-PD-L1 peptide can be delivered stably and efficiently to the inside of the tumor due to the characteristics of Salmonella, and can exhibit an anti-tumor effect by inducing the activation of T cells through the formation of a bond with PD-1 of cancer cells, thereby using the Salmonella mutant strain or the membrane vesicles thereof for cancer treatment.

ANTI-BACTERIAL PROTEIN COMPLEX

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

Composition or kit for detecting animal intestinal microorganism

Resumen de: KR20250155130A

본 발명은 서울특별시 서울기술연구원 2022년도 캠퍼스타운 기술매칭 지원사업(반려동물 장내미생물 자가검사키트)을 통해 개발된 기술이다. 본 발명은 동물의 장내미생물 검출용 조성물 또는 키트에 관한 것으로서, 본 발명의 조성물 또는 키트는 미생물 유래 독소에 특이적으로 결합할 수 있는 물질을 프로브로 포함함으로써, 시중에 널리 사용되는 코로나 자가검진 키트와 마찬가지로 소비자 스스로 반려동물의 장내미생물을 검사할 수 있도록 하고, 이에 따라 반려동물의 장내미생물 분석에 대한 소비자 접근성을 크게 향상시킬 수 있다.

HOST CELL PROTEIN DETECTION USING LATERAL FLOW DEVICES

Resumen de: WO2025224621A1

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.

MODIFIED MICROORGANISMS

Resumen de: WO2025224251A1

The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.

VACUOLE ESCAPE

Resumen de: WO2025224268A1

The present invention relates to a live attenuated Gram-negative bacterium modified to enable enhanced vacuole escape. In particular, the invention relates to a live attenuated Gram-negative bacterium comprising a heterologous polynucleotide encoding a prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein said heterologous polynucleotide encoding the prokaryotic disulfide bond isomerase is operably linked to a promoter, or a live attenuated Gram-negative bacterium comprising an endogenous prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein the endogenous prokaryotic disulfide bond isomerase is upregulated compared to its basal level expression.

SYSTEMS, METHODS, AND COMPOSITIONS FOR THE DETECTION OF MICROBES

Resumen de: AU2024264505A1

Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.

METHOD FOR DETECTING FOODBORNE PATHOGENS USING BACTERIOPHAGES

Resumen de: WO2025225874A1

The present invention relates to a method for detecting live foodborne pathogens using novel bacteriophages LEC1, LBC9, and LSE2. By using this method, Escherichia coli, Bacillus cereus, and Salmonella spp., which are live foodborne pathogens in food, can be rapidly and accurately detected at the same time, and thus the method can be effectively used for preventing food poisoning.

HOST CELL PROTEIN DETECTION USING LATERAL FLOW DEVICES

Resumen de: US2025334572A1

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.

METHODS AND SYSTEMS FOR THE RAPID DETECTION OF LISTERIA USING INFECTIOUS AGENTS

Resumen de: EP4641200A2

Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

BACTERIOPHAGES AND USE THEREOF FOR THE TREATMENT OR PREVENTION OF INFECTION CAUSED BY SALMONELLA GALLINARUM

Resumen de: WO2024137831A2

A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.

- Recombinant Microbials Expressing Strep-tag and Tumor Imaging Aduvant Comprising the Microbials

Resumen de: KR20240012662A

The present invention relates to a genetic construct characterized in that the anti-sigma factor flgM gene and the gene encoding strep-tag are linked to encode a fusion protein of flgM and strep-tag so that a strep-tag may be expressed on the surface of an anticancer strain that may be targeted to a tumor site and stimulate immune activity, and an anticancer adjuvant and a tumor imaging aid which is transformed thereby and exhibits anticancer activity itself and may be usefully used for the diagnosis and treatment of tumor cells together with an anticancer substance or contrast agent labeled with a substance which specifically reacts with the strep-tag.

一种用于防治多种致病性肠杆菌感染的融合蛋白及应用

Resumen de: CN120842432A

本发明涉及一种应对多种致病性肠杆菌感染防治的融合蛋白、免疫原性组合物、重组简并疫苗，以及分子架构设计和应用等。本发明筛选到3种细胞免疫抗原Tuf、DnaK、fusA，构建的3种抗原的融合蛋白分子可显著抑制多种肠杆菌感染引起的组织病变，具有良好的免疫原性，起到有效防治和免疫保护作用，广谱且高效地预防多种致病性肠杆菌感染，具有广阔的工业应用前景。

免疫原性组合物

Resumen de: WO2024192346A1

Technologies for providing immunogenic compositions (e.g., vaccines) and methods of inducing immune responses in subjects in need thereof.

- Recombinase polymerase amplification primer sets for detecting Salmonella and uses thereof

Resumen de: KR20250151120A

본 발명은 살모넬라(Salmonella) 검출을 위한 재조합효소-중합효소 증폭법(recombinase polymerase amplification)용 프라이머 세트 및 이를 이용한 핵산 측면 흐름 면역 분석(nucleic acid lateral flow immunoassay)용 살모넬라(Salmonella) 검출용 키트에 관한 것으로, 본 발명의 프라이머 세트는 살모넬라(Salmonella)속에 특이적인 유전자인 invA 유전자를 가장 높은 효율로 증폭하여 살모넬라(Salmonella) 검출이 우수할 뿐만 아니라, 재조합효소-중합효소 증폭(recombinase polymerase amplification) 수행시 비교적 낮은 온도에서 짧은 시간안에 증폭이 용의할 뿐만 아니라 상기 프라이머 세트의 역방향 프라이머 말단에 제1 표지물질이 결합하여 검출 가능한 발색입자인 금나노입자가 결합되고, 상기 프라이머 세트가 증폭하는 서열의 일부 서열에 특이적으로 결합하는 부위를 포함하는 프로브는 5' 말단에 제2 표지물질이 결합하여 핵산 측면 흐름 면역 분석(nucleic acid lateral flow immunoassay)에 적용시 RPA 증폭산물을 쉽게 검출 할 수 있는 살모넬라(Salmonella) 검출용 프라이머 세트 및 이의 용도를 제공한다.

STRUCTURED MICROGEL ELECTROPHORETIC ARRAYS FOR RAPID MULTIPLEX NUCLEIC ACID DETECTION

Nº publicación: US2025321205A1 16/10/2025

Solicitante:

ADOR DIAGNOSTICS LTD [CY]
ADOR DIAGNOSTICS LTD